Russia has approved R-Pharm’s Coronavir treatment for outpatients with mild to moderate COVID-19 infections and the antiviral drug could be rolled out to pharmacies in the country as soon as next week, said the company.
Coronavir’s approval follows the green light for another Russian COVID-19 drug, Avifavir, in May. Both are based on favipiravir, which was developed in Japan and is widely used as the basis for viral treatments.
R-Pharm’s announcement is another sign Russia is pushing hard to take a global lead in the race against the virus. It is already exporting its COVID-19 tests and has clinched several international deals for supplies of its Sputnik V vaccine.